Photo by nci from unsplash
• Bioresorbable vascular scaffolds (BVS) intend to overcome long-term limitations of permanent metallic coronary stent implants, particularly in the proinflammatory, prothrombotic diabetic milieu. • The Amsterdam Investigator-Initiated Absorb Strategy All-Comers… Click to show full abstract
• Bioresorbable vascular scaffolds (BVS) intend to overcome long-term limitations of permanent metallic coronary stent implants, particularly in the proinflammatory, prothrombotic diabetic milieu. • The Amsterdam Investigator-Initiated Absorb Strategy All-Comers (AIDA) trial demonstrates worse 3year outcomes with everolimus-eluting poly-L-lactide BVS than everolimus-eluting stents (EES) in both diabetics and non-diabetics. A larger sample-size patientlevel meta-analysis finds significantly increased risk of early and very late BVS thrombosis in diabetics. • While no current clinical evidence supports the BVS hypothesis of improving outcomes in diabetics compared to EES, follow-up beyond the 3-year device resorption phase and current generation device and implantation technique improvements provide the unlikely possibility of a useful niche for the everolimus-eluting poly-L-lactide BVS.
Journal Title: Catheterization and Cardiovascular Interventions
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!